Many institutions now cover OA publishing costs for affiliated researchers, as part of an OA agreement with Springer Nature. Find out more about OA agreements and whether you may be entitled to publish OA with your fees covered.
Check your eligibility to publish open access with your fees covered
Thematic Series
- World Aids Day
- Retroviruses & the Microbiome
- The multifaceted regulation of transcription in animal and human retroviruses, endogenous retroviruses
- HIV infection of uncommon host cells
- Applications of CRISPR-Cas and genome editing techniques for established and emerging infectious diseases
- Previous Thematic Series
World Aids Day
December 1st marks World AIDS Day, a globally recognized occasion dedicated to raising awareness of the AIDS pandemic and mourning those we have lost.
This cross-journal collection focuses on exploring the effects and consequences of long-term HIV infection, advances in treatment, epidemiological studies and global health, and more.
Retroviruses & the Microbiome
The focus of this issue is to move beyond associations to mechanisms and functional interactions, including both replication-competent and endogenous retroviruses, human and non-human hosts, and implications for homeostasis, disease and/or therapeutics.
Deadline for submissions: 20 May 2024
The multifaceted regulation of transcription in animal and human retroviruses, endogenous retroviruses
Retroviruses are enveloped viruses with a capsid containing two copies of the viral genomic positive sense single-stranded RNA. Retroviruses are responsible for a broad range of diseases in animals and humans, the most common of which is the development of cancers.
HIV infection of uncommon host cells
This collection aims to provide a state of the art critical evaluation of HIV infection of atypical cells, their role in pathogenesis and the challenges that they might present when developing and evaluating approaches towards an HIV cure.
Applications of CRISPR-Cas and genome editing techniques for established and emerging infectious diseases
The simplicity and broad applicability of targeted and programmable genome editing approaches, including but not limited to those based on CRISPR-Cas9, raise the possibility of a new way to treat a variety of infections, as well as numerous therapeutic strategies for common diseases. This series aims to build a collection of articles that will highlight current developments in this area.
Previous Thematic Series
The Capsid Protein, a Master Regulator of HIV-1 Replication
Edited by Felipe Diaz-Griffero
HIV Intervention Using Mouse Models for Viruses
Edited by J Victor Garcia-Martinez and Angela Wahl
Endogenous Retroviruses in Evolution and Disease
Cross-journal collection
HTLV-1: a re-emerging human pathogen
Edited by Genoveffa Franchini and Cynthia Masison
Broadly neutralizing antibodies (bnAbs) against HIV
Edited by Rogier Sanders and Marit van Gils
Measuring HIV-1 persistence in vivo
Edited by Ben Berkhout and Alexander Pasternak
Disruptive technologies in retrovirus research
Edited by Johnson Mak
Articles
-
-
Retroviral foamy virus gag induces parkin-dependent mitophagy
-
Therapeutic efficacy of albuvirtide-based antiretroviral therapy in people living with HIV who have low-level viremia and non-AIDS-defining malignancies: two case reports
-
Aberrant expression of human endogenous retrovirus K9-derived elements is associated with better clinical outcome of acute myelocytic leukemia
-
Partial waivers: PEPFAR’s 2025 funding suspension and the looming HIV/AIDS catastrophe in Sub-Saharan Africa
-
Can immunotherapy be useful as a “functional cure” for infection with Human Immunodeficiency Virus-1?
-
Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells enhances anti-viral immunity during chronic retroviral infection
-
The role of antigen presenting cells in the induction of HIV-1 latency in resting CD4+ T-cells
-
A reflection on HIV/AIDS research after 25 years
-
The discovery of endogenous retroviruses
Latest Tweets
View Twitter timeline
Your browser needs to have JavaScript enabled to view this timeline
Announcing the launch of In Review
Retrovirology, in partnership with Research Square, is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
Nominations for the KT Jeang Retrovirology Prize now open
Nominations for the 2025 KT Jeang Retrovirology Prize are now open until June 8th. It's awarded annually to a colleague who has made outstanding contributions to the field of Retrovirology and is in the middle of their career. Learn more about the prize as well as how to nominate researchers here.
Johnson Mak Among 65 Fellows Elected to the American Academy of Microbiology
The American Academy of Microbiology (the Academy) has elected Johnson Mak, co-Editor-in-Chief of Retrovirology, and 64 peers to the Class of 2025. Fellows of the American Academy of Microbiology, an honorific leadership group within the American Society for Microbiology (ASM), are elected annually through a highly selective, peer-review process, based on their records of scientific achievement and original contributions that have advanced microbiology. The Academy received 146 nominations this year, electing 65 into the 2025 Fellowship Class.
“Fellows are pioneers in their field, driving discovery and innovation that push the boundaries of science and benefit society at large,” said Vanessa Sperandio, Ph.D., Chair of the Academy Governors. “Being named an Academy Fellow is a prestigious honor, and I am thrilled to extend my congratulations and warm welcome to Johnson Mak as a member of the 2025 Cohort.”
You can learn more about the 2025 Fellowship Class here.
Retrospective Collection: Human Retroviruses and AIDS
This retrospective collection collates recently published notable papers on HIV and retrovirus research from the journals AIDS Research and Therapy and Retrovirology.
Aims and scope
Retrovirology is an open access, online journal that publishes stringently peer-reviewed, high-impact articles on host-pathogen interactions, fundamental mechanisms of replication, immune defenses, animal models, and clinical science relating to retroviruses and retrovirus-related diseases. Retroviruses are pleiotropically found in animals. Well-described examples include avian, murine and primate retroviruses.
Two human retroviruses are especially important pathogens. These are the human immunodeficiency virus, HIV, and the human T-cell leukemia virus, HTLV. HIV causes AIDS while HTLV-1 is the etiological agent for adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis. Retrovirology aims to cover comprehensively all aspects of human and animal retroviral research.
Editors-in-Chief
Johnson Mak, PhD, Institute for Glycomics, Griffith University, Australia
Susan Ross, University of Illinois at Chicago, USA
Editor Emeritus
Andrew Lever, PhD, University of Cambridge (Emeritus Professor), UK
Founding Editor
Kuan-Teh Jeang, MD, PhD, National Institutes of Health, USA (1958-2013)
Why publish your article in Retrovirology?
- We welcome research from across the entire field of retroviruses, supporting the research community with a progressive and inclusive approach.
- Ranked among the top virology journals worldwide, we publish high quality research and expert reviews across basic science, translational, and clinical research.
- Our expert and highly responsive team of Editors provides excellent service throughout, with rapid evaluation and publication of research with broad and lasting impact.
- Founded in 2004, we are one of the leading influencers in HIV/AIDS and retrovirus research, reaching a large global audience.
Follow
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 2.7
5-year Journal Impact Factor: 3.1
Source Normalized Impact per Paper (SNIP): 0.707
SCImago Journal Rank (SJR): 0.845Speed 2024
Submission to first editorial decision (median days): 7
Submission to acceptance (median days): 108Usage 2024
Downloads: 1,138,806
Altmetric mentions: 337